Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

ADC Therapeutics (ADCT) Operating Expenses (2019 - 2026)

ADC Therapeutics has reported Operating Expenses over the past 8 years, most recently at $46.1 million for Q1 2026.

  • Quarterly results put Operating Expenses at $46.1 million for Q1 2026, down 10.49% from a year ago — trailing twelve months through Mar 2026 was $156.5 million (up 2.96% YoY), and the annual figure for FY2022 was $4.8 billion, up 7.3%.
  • Operating Expenses reached $46.1 million in Q1 2026 per ADCT's latest filing, down from $47.4 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $5.0 billion in Q3 2022 and bottomed at -$86.9 million in Q1 2022.
  • Median Operating Expenses over the past 5 years was $49.0 million (2023), compared with a mean of $369.7 million.
  • The largest annual shift saw Operating Expenses soared 7077.83% in 2022 before it tumbled 98.98% in 2023.
  • Over 5 years, Operating Expenses stood at -$80536.0 in 2022, then skyrocketed by 62981.2% to $50.6 million in 2023, then increased by 6.69% to $54.0 million in 2024, then decreased by 12.28% to $47.4 million in 2025, then fell by 2.74% to $46.1 million in 2026.
  • Business Quant data shows Operating Expenses for ADCT at $46.1 million in Q1 2026, $47.4 million in Q3 2025, and $63.0 million in Q2 2025.